Inactive Instrument

Audentes Therapeutics, Inc.

Equities

US05070R1041

Biotechnology & Medical Research

Audentes Therapeutics, Inc. Plans to Build New Gene Therapy Manufacturing Facility in Sanford, North Carolina

February 18, 2020 at 02:26 pm EST

Audentes Therapeutics, Inc. announced that it plans to invest $109 million to build a new 135,000 square foot, gene therapy manufacturing facility in Sanford, North Carolina. The initial phase of the capital investment is planned to occur over approximately 18 months, and the plant is expected to be operational in 2021. The remaining investment will take place over two additional planned expansion phases. The company plans to create over 200 new jobs in Lee County.

Latest news about Audentes Therapeutics, Inc.

Cartesian Therapeutics, Inc Receives Notice from Audentes Therapeutics, Inc of Astellas? Termination of the License and Development Agreement	Mar. 14	CI
Taysha Gene Therapies, Inc. announced that it has received $79.99982 million in funding from Astellas Pharma Inc., Audentes Therapeutics, Inc.	22-11-07	CI
Taysha Gene Therapies, Inc. announced that it expects to receive $79.99982 million in funding from Astellas Pharma Inc., Audentes Therapeutics, Inc.	22-10-20	CI
Audentes Therapeutics, Inc. Announces FDA Lifts Hold on ASPIRO Clinical Trial of AT132 for Treatment of X-Linked Myotubular Myopathy	20-12-24	CI
Audentes Therapeutics Provides Update on the ASPIRO Clinical Trial Evaluating AT132 in Patients with X-Linked Myotubular Myopathy	20-08-21	CI
Audentes Therapeutics, Inc. Appoints Julie Person as Senior Vice President, Human Resources	20-04-21	CI
Audentes Therapeutics, Inc. Plans to Build New Gene Therapy Manufacturing Facility in Sanford, North Carolina	20-02-18	CI
Audentes Therapeutics, Inc. Announces Management Changes	20-01-15	CI
Audentes Therapeutics, Inc. Approves a Change in the Company’s Fiscal Year to End on March 31	20-01-15	CI
Audentes Therapeutics, Inc.(NasdaqGM:BOLD) dropped from S&P TMI Index	20-01-15	CI
Audentes Therapeutics, Inc.(NasdaqGM:BOLD) dropped from S&P Biotechnology Select Industry Index	20-01-15	CI
Audentes Therapeutics, Inc.(NasdaqGM:BOLD) dropped from S&P Global BMI Index	20-01-15	CI
Audentes Therapeutics, Inc.(NasdaqGM:BOLD) dropped from NASDAQ Composite Index	20-01-14	CI
Audentes Therapeutics, Inc.(NasdaqGM:BOLD) dropped from NASDAQ Biotechnology Index	20-01-14	CI
Astellas US Holding, Inc. completed the acquisition of Audentes Therapeutics, Inc..	20-01-13	CI
Takeda Pharmaceutical : Astellas ramps up M&A, buys U.S. biotech Xyphos for as much as $665 million	19-12-26	RE
Roche : dives deeper into gene therapy with $1.15 billion Sarepta licensing deal	19-12-23	RE
Japanese shares slip on concerns of longer trade war	19-12-03	RE
Wall Street falls as trade hopes wane	19-12-03	RE
Astellas Pharma : Japan's Astellas to buy Audentes for $3 billion in high-priced gene therapy bet	19-12-03	RE
Nikkei slips on fresh global trade concerns, weak U.S. data	19-12-03	RE
Astellas US Holding, Inc. entered into a definitive agreement to acquire Audentes Therapeutics, Inc. for $2.8 billion.	19-12-01	CI
Audentes Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-07	CI
Transcript : Audentes Therapeutics, Inc., Q3 2019 Earnings Call, Nov 07, 2019	19-11-07
Audentes Therapeutics Announces New Positive Data from ASPIRO	19-10-09	CI

Chart Audentes Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company's subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.63%	103B
REGENERON PHARMACEUTICALS, INC.	+1.62%	95.28B
ARGENX SE	+1.46%	22.15B
BIONTECH SE	-16.67%	21.02B
GENMAB A/S	-8.58%	18.15B
WUXI APPTEC CO., LTD.	-38.74%	16.73B
BEIGENE, LTD.	-13.21%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+5.41%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.57%	12.17B

Bio Therapeutic Drugs